MannKind Corp. (MNKD) Wednesday reported positive preliminary results from Study 175 and Study 171, two Phase 3 clinical studies of Afrezza Inhalation Powder, an investigational, ultra rapid-acting mealtime insulin therapy administered using MannKind's next-generation inhaler, also known as the Dreamboat inhaler. The studies also met primary endpoints.
MannKind said study 175 recorded superior reductions in A1c levels in type 2 patients and reduced glucose excursions after food intake. In study 171 in type 1 patients, significantly less hypoglycemia and reduction in fasting blood sugar noticed.
Study 171 was an open-label study involving 518 patients with type 1 diabetes on basal/bolus insulin therapy who were studied at sites in the United States, Russia, Ukraine and Brazil. Study 175 was a double-blind, placebo-controlled study involving 353 patients with type 2 diabetes whose disease was inadequately controlled on metformin with or without a second or third oral medication.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.